Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19
The primary objective of this research study is to assess Radiation Oncology healthcare providers (i.e. faculty, residents and advanced practice providers (APPs) implementation and perception of telehealth for on treatment patients in lieu of in person on treatment visits during standard of care radiotherapy during COVID-19.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Feb 6, 2026 · Source: ClinicalTrials.gov
Participation is limited to people invited by the study team.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Duke University
- Interventions being studied
- Other: Telehealth
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
started outpatient radiation therapy with or without concurrent systemic therapy at Duke Cancer Center during the COVID-19 outbreak
- undergoing total body radiation therapy for hematopoetic stem cell transplantation
- undergoing therapy as inpatient
- completed radiation therapy prior to algorithm execution
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Duke Cancer CenterDurham, North Carolina
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 6, 2026. Always confirm current availability with the study team.